Integra LifeSciences (IART) Tops Q3 EPS by 11c, provides guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.54, $0.11 better than the analyst estimate of $0.43. Revenue for the quarter came in at $402.06 million versus the consensus estimate of $414.23 million.

GUIDANCE:

Integra LifeSciences sees Q4 2025 EPS of $0.79-$0.84, versus the consensus of $0.92. Integra LifeSciences sees Q4 2025 revenue of $420-440 million, versus the consensus of $456.2 million.

Integra LifeSciences sees FY2025 EPS of $2.19-$2.24, versus the consensus of $2.21. Integra LifeSciences sees FY2025 revenue of $1.62-1.64 billion, versus the consensus of $1.67 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance